Core Insights - Philips has demonstrated strong order growth and sales in 2025, with a robust balance sheet and margin expansion despite external challenges [2][6][7] Financial Performance - For the full year 2025, comparable order intake increased by 6%, while comparable sales growth was 2%. In Q4, comparable order intake rose by 7%, and group sales reached EUR 5.1 billion, reflecting a 7% increase [6][7] - Adjusted EBITA margin improved by 80 basis points to 12.3% for the full year and by 160 basis points to 15.1% in Q4, driven by higher sales and productivity [6][7] - Free cash flow for 2025 was EUR 512 million, with Q4 free cash flow at EUR 1,200 million [6][8] Segment Performance - Diagnosis & Treatment segment saw a 4% increase in comparable sales in Q4, with an adjusted EBITA margin of 11.8% [9] - Connected Care segment experienced a 7% increase in comparable sales in Q4, with an adjusted EBITA margin of 16.5% [10] - Personal Health segment reported a 14% increase in comparable sales in Q4, with an adjusted EBITA margin of 23.0% [11] Innovation and Strategic Initiatives - Philips launched several innovations, including the Azurion neuro biplane platform and a helium-free 3.0T MR system, enhancing its product offerings in healthcare [3][15] - The company has entered a five-year strategic partnership with AdventHealth to upgrade patient monitoring systems across its network [15] - Philips aims to drive profitable growth through segment-specific strategies, innovation, and disciplined execution, with a focus on integrating AI and data into healthcare solutions [19][20][21] Future Outlook - For 2026, Philips anticipates mid-single-digit comparable sales growth CAGR and a mid-teens adjusted EBITA margin by 2028 [24][23] - The company plans to achieve cumulative free cash flow of EUR 4.5-5.0 billion over the 2026-2028 period and EUR 1.5 billion in productivity savings [24]

Group 1 - Royal Philips intends to extend the settlement of two forward contracts for 2 million long-term incentive plan shares each, postponing the maturity dates from Q4 2025 to Q4 2026 as part of its share repurchase program announced on June 14, 2023 [1] - Philips generated sales of EUR 18 billion in 2024 and employs approximately 67,300 employees, with operations in over 100 countries [3] - The company focuses on health technology, emphasizing patient- and people-centric innovation to improve health and well-being through advanced technology and clinical insights [2][3] Group 2 - Philips is a leader in various sectors including diagnostic imaging, ultrasound, image-guided therapy, monitoring, enterprise informatics, and personal health [3] - The company’s share repurchase program is part of its broader strategy to enhance shareholder value [1]

Group 1 - Royal Philips announced a dividend exchange ratio of 1 new common share for every 23.6353 existing common shares, based on a volume weighted average price of EUR 20.0600, resulting in a gross dividend in shares of approximately EUR 0.85 [1] - A total of 22,980,748 new common shares will be issued as part of the dividend distribution [1] - Shareholders had the option to choose between a dividend in shares or cash, with 41.4% opting for cash, which is below the 50% maximum threshold [2] Group 2 - The delivery of new common shares and payment of cash dividends will occur from June 6, 2025, with the total issued share capital reaching EUR 192,584,026, equivalent to 962,920,132 common shares [3] - Royal Philips generated sales of EUR 18 billion in 2024 and employs approximately 67,200 people across more than 100 countries [5] - The company is a leader in health technology, focusing on diagnostic imaging, ultrasound, image-guided therapy, monitoring, and personal health solutions [5]

Group 1 - Royal Philips announced a dividend exchange ratio of 1 new common share for every 23.6353 existing common shares, based on a volume weighted average price of EUR 20.0600, resulting in a gross dividend in shares of approximately EUR 0.85 [1] - A total of 22,980,748 new common shares will be issued as part of the dividend distribution [1] - Shareholders had the option to choose between a dividend in shares or cash, with 41.4% opting for cash, which is below the 50% maximum threshold [2] Group 2 - The delivery of new common shares and payment of cash dividends will occur from June 6, 2025, with the total issued share capital reaching EUR 192,584,026, equivalent to 962,920,132 common shares [3] - Royal Philips generated sales of EUR 18 billion in 2024 and employs approximately 67,200 people across more than 100 countries [5] - The company is a leader in health technology, focusing on diagnostic imaging, ultrasound, image-guided therapy, monitoring, and personal health solutions [5]